NEWTON, Mass.--(BUSINESS WIRE)--June 6, 2006--Clinical Data, Inc. (NASDAQ: CLDA - News), a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as genetic tests to improve patient care, announced today that its PGxHealth(TM) division will provide a genetic test to clinicians that is associated with response to warfarin, a commonly prescribed drug to treat and prevent blood clots associated with stroke, heart attack, and other clotting disorders.
